Skip Navigation

Cardiovascular Research 2005 66(3):562-573; doi:10.1016/j.cardiores.2005.01.026
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Valle, I.
Right arrow Articles by Monsalve, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valle, I.
Right arrow Articles by Monsalve, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

PGC-1{alpha} regulates the mitochondrial antioxidant defense system in vascular endothelial cells

Inmaculada Vallea,b,c, Alberto Álvarez-Barrientosb, Elvira Arzab, Santiago Lamasa,b,c,* and María Monsalvea,b,c,*

aCentro de Investigaciones Biológicas (Consejo Superior de Investigaciones Científicas), Ramiro de Maeztu, 9 28040, Madrid, Spain
bCentro Nacional de Investigaciones Cardiovasculares (Instituto de Salud Carlos III), Ronda de Poniente, 5 Tres Cantos 28760, Madrid, Spain
cInstituto "Reina Sofía de Investigaciones Nefrológicas", Spain

* Corresponding authors. Centro Nacional de Investigaciones Cardiovasculares (Instituto de Salud Carlos III), Ronda de Poniente, 5 Tres Cantos 28760-Madrid, Spain. Tel.: +34 918061880x1140; fax: +34 918035258. Email address: mmonsalve{at}cnic.es

Received 29 November 2004; revised 17 January 2005; accepted 26 January 2005


   Abstract
Top
 Abstract
1. Introduction
 2. Methods
 3. Results
 4. Discussion
 References
 
Objective: Mitochondrial production of oxidants contributes to a variety of pathological conditions including the vascular complications of diabetes, neurodegenerative diseases, and cellular senescence. We postulated that a transcriptional coactivator, peroxisome proliferator activated receptor-{gamma} coactivator 1{alpha} (PGC-1{alpha}), a major regulator of oxidative metabolism and mitochondrial biogenesis, could be involved in the transcriptional regulation of the mitochondrial antioxidant defense system in vascular endothelial cells.

Methods and results: We show that PGC-1{alpha} is present in human, bovine, and mouse endothelial cells and positively modulates the expression of the mitochondrial detoxification system. Endothelial cells that overexpress PGC-1{alpha} show reduced accumulation of reactive oxygen species (ROS), increased mitochondrial membrane potential, and reduced apoptotic cell death both in basal and oxidative stress conditions. Downregulation of PGC-1{alpha} levels by siRNA reduces the expression of mitochondrial detoxification proteins.

Conclusions: These results unveil a novel regulatory pathway that links mitochondrial activity and mitochondrial oxidative stress protective systems. In addition, they suggest that PGC-1{alpha} could play a crucial protective role in vascular complications of diabetes, where the mitochondrial metabolism of glucose has been shown to result in oxidative stress and vascular endothelial cell dysfunction.

KEYWORDS PGC-1{alpha}; Endothelium; Oxidative stress; Mitochondria; Glucose


   1. Introduction
Top
 Abstract
 1. Introduction
2. Methods
 3. Results
 4. Discussion
 References
 
Excessive production of reactive oxygen species (ROS) in the mitochondria plays a major role in the development of several diseases including the vascular and neurological complications of diabetes [29,46], neurodegenerative diseases like Parkinson's disease [13], Alzheimer [1] and epilepsy [9], ageing [11] and cancer [31,32]. In diabetic patients, hyperglycemia causes increased ROS production [29] that eventually leads to endothelial dysfunction. Endothelial dysfunction is a sensitive indicator of cardiovascular disease, predicts its prognosis and is closely associated with the development of atherosclerosis [7].

The Peroxisome Proliferator Activated Receptor (PPAR) {gamma} Coactivator 1-{alpha} (PGC-1{alpha}) [42] is a transcriptional coactivator identified as an upstream regulator of lipid catabolism, mitochondrial number and function. Consistent with its emerging role as a central regulator of energy metabolism, PGC-1{alpha} is abundantly expressed in tissues with high metabolic rates.

Increased mitochondrial activity and electron flow through the ETC (electron transport chain) may be responsible for an increased production of superoxide (O2–) [20], that when dismutated generates the highly toxic hydrogen peroxide (H2O2), unless adequate detoxification mechanisms are activated. We postulated the existence of a mechanism for the coordinated regulation of mitochondrial oxidative metabolism and ROS protection systems should exist. As PGC-1{alpha} is known to regulate mitochondrial activity, we decided to test whether PGC-1{alpha} could play such a role. This idea was supported by recent observations that indicated increased levels of Manganese Superoxide Dismutase (MnSOD) mRNA in C2C12 myotubes that overexpressed PGC-1{alpha} [39]. As a model system we chose primary endothelial cells, where excessive production of O2– and H2O2 in the mitochondria has been shown to mediate high-glucose dependent oxidative stress [29].

Until recently, the only well-known antioxidant mitochondrial protein was MnSOD [25]. A complete mitochondrial detoxification system has now been described. It is composed of Peroxiredoxin III [44], Peroxiredoxin V [18], mitochondrial Thioredoxin [37], mitochondrial Thioredoxin Reductase [8,22,26,41], and mitochondrial splicing variants of Glutaredoxin [24] and Glutathione Reductase [16]. The mitochondrial Uncoupling Protein 2 (UCP-2) forms a proton channel that has been proposed to prevent superoxide production [5,21].

We found that PGC-1{alpha} expression in primary endothelial cells results in the up-regulation of mitochondrial number and activity and of a full set of oxidative stress protective genes. This regulatory activity helps to prevent increased ROS accumulation, endothelial dysfunction and apoptosis in high glucose conditions.


   2. Methods
Top
 Abstract
 1. Introduction
 2. Methods
3. Results
 4. Discussion
 References
 
2.1. Cell culture
Human Umbilical Vein Endothelial Cells (HUVEC) were isolated from umbilical cord veins and cultured as previously described [28]. Umbilical cords were obtained from Ruber International Hospital (Madrid, Spain) with the approval of the donors and the ethics committee of the institution. Bovine Aortic Endothelial Cells (BAEC) from bovine aortas were isolated and cultured as previously described [23]. Aortas were obtained from an authorized slaughterhouse. Mouse Aortic Endothelial Cells (MAEC) were isolated and cultured as previously described [14] from C57B mice provided by our animal facility. The protocols used conform to the Declaration of Helsinki and to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institute of Health (NIH Publication No. 85-23).

2.2. Adenoviral vectors and infection
Three copies of the HA tag were inserted at the N-terminus of PGC-1{alpha}, and subcloned in pShuttle-CMV (Quantum). Adenoviruses were generated and purified according to the manufacturer's instructions. Confluent HUVEC or BAEC cells were exposed to adenoviral vectors at an moi of 50 for 12 h.

2.3. RNA purification and analysis
Total RNA was isolated with Trizol. The expression levels were determined by reverse transcription (RT) of total RNA followed by PCR analysis (RT-PCR). One microgram of total RNA was reverse transcribed by extension of random primers. The PCR program used was as follows: 2 min at 94 °C; 30–40 cycles of 30'' at 92 °C, 30'' at 55 °C and 30'' at 72 °C; and a final extension step of 5' at 72 °C. A PCR reaction was also performed on total RNA that had not been reverse transcribed to control for the absence of genomic DNA amplification. PCR products were resolved on 1% agarose gels. Relative expression levels were determined by Real-Time PCR (rPCR) in a 7000 Sequence Detection System (Applied Biosystem). Thermal conditions were: 2' at 50 °C, 10' at 95 °C; and 45 cycles of 15'' at 95 °C, 30'' at 55–60 °C, 30'' at 72 °C.

2.4. Western blot
Whole-cell extracts (WCE) were prepared as previously described [27]. Protein samples were resolved on SDS-PAGE, transferred onto ImmobilonTM-P membrane (Millipore), and analyzed by Western blotting with chemi-luminescence detection (ECL, Amersham).

2.5. siRNA
The siRNAs were synthesized using the Silencer siRNA Construction Kit from Ambion, from the following DNA oligos:

GAPDH siRNA: Sense control DNA and Antisense Control DNA (provided with the kit)
PGC-1{alpha} siRNA: 585/s 5'-aacgctttattgctccatgaacctgtctc-3', 585/as 5'-aattcatggagcaataaagcgcctgtctc-3.

1 µg of siRNA was transfected into 70% confluent BAEC cells grown on 6 well plates with Lipofectamine 2000 (Invitrogen), following the manufacturer's instructions. Cells were harvested 48 h post-transfection.

2.6. Apoptosis
2.6.1. Flow cytometry
Cells were resuspended in 100 µl of annexin-binding buffer (10 mM HEPES, 140 mM NaCl and 25 mM CaCl2, pH 7.4), plus 2.5 µl of Alexa fluor 488 annexin V conjugate. Cells were incubated at room temperature (RT) for 15 min prior to the addition of 400 µl of annexin-binding buffer, and propidium iodide (PI) 2 µg/ml final concentration. Following an additional 10-min incubation period, the cells were analyzed on a CYAN MLE (Dako Cytomation).

2.6.2. Caspase 3 and Caspase 9 activity
2.6.2.1. Confocal microscopy
Cells were grown on glass bottom dishes, incubated for 30 min at RT with 0.1% substrates of Caspases 3 (FITC-DEVD-FMK) or 9 (Red-LEHD-FMK), plus 0.1% HOECHST42, and visualized on a Radiance 2100 confocal microscope (BioRad). Control samples were pre-incubated with the caspase inhibitor Z-VAD.

2.6.2.2. Fluorimetric quantification
50 µl of WCE (1 mg/ml) were incubated with fluorescent substrates for Caspase-3 and Caspase-9 at 20 µM final concentration. The fluorescent products were detected in a FluoroscanAscent (Thermo Labsystems).

2.7. Mitochondrial transmembrane potential ({Delta}{Psi}m)
Changes in {Delta}{Psi}m were determined as differences in the tetramethylrhodamine methyl ester (TMRM) versus MitoTracker Green signal ratio. Fluorochromes were added to the cell culture medium at 50 nM. Cells were incubated for 30 min at 37 °C, trypsinized and resuspended in PBS. Fluorescence intensity was measured by flow cytometry.

2.8. Reactive oxygen species
Cells were incubated with 2 µM 5-chloromethyl-2' 7'-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA) for 30 min (added directly to the media). The cells were then trypsinized and resuspended in PBS. Fluorescence intensity was measured by flow cytometry.

2.9. Chromatin immunoprecipitation (ChIP)
The experimental conditions used have been described previously [35]. PGC-1{alpha} was immunoprecipitated with a polyclonal {alpha}-PGC-1{alpha} antibody. The immunoprecipitated DNA was analyzed by rPCR.

2.10. Statistics
Data are expressed as means ± S.D. values. Statistical evaluation of the data was performed by analysis of variance (ANOVA) or non-parametric tests as appropriate. Values were considered to be statistically significant at P<0.05. n ≥ 3 in all the experiments.

2.11. Materials
DMNQ (2,3-dimetoxi-1-naphthoquinone) was from Calbiochem. Trizol reagent is from Invitrogen. 488 annexin V conjugate, CM-H2DCFDA, TMRM and MitoTracker Green were from Molecular Probes. The fluorescent substrates for Caspase-3 (Ac-DEVD-AMC) and Caspase-9 (Ac-LEHD-AFC) were from PharMingen and Biochem. Substrates of Caspases (CaspGLOW staining kit) were from Alexis Biochemicals, HOECHST42 was from Sigma.

The following antibodies were used: Mouse monoclonal {alpha}-cytochrome c (Clone 7H8.2C12) was purchased from BD PharMingen; mouse monoclonal {alpha}-Peroxiredoxin-V (Clone 44) was from BD Biosciences; mouse monoclonal {alpha}-GAPDH was from Chemicon and rabbit polyclonal {alpha}-Caspase-3 (H-277), {alpha}-PGC-1 (H-300) and {alpha}-UCP-2 (C-20) antibodies were from Santa Cruz Biotechnology. Rabbit polyclonal {alpha}-MnSOD (SOD-110) was from Stressgen; rabbit polyclonal {alpha}-catalase was from Chemicon Int.; and rabbit polyclonal {alpha}-Peroxiredoxin III, {alpha}-Thioredoxin 2 and {alpha}-Thioredoxin Reductase 2 were form LabFrontiers. Horseradish peroxidase-conjugated secondary antibodies were from Santa Cruz Biotechnology ({alpha}-goat) and Amersham ({alpha}-rabbit and {alpha}-mouse).


   3. Results
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
4. Discussion
 References
 
3.1. PGC-1{alpha} is present in vascular endothelial cells
PGC-1{alpha} is a highly regulated protein and its levels vary greatly among tissues and in changing metabolic situations[33]. It was therefore important to determine if PGC-1{alpha} was present in the vascular endothelium. We tested HUVEC and BAEC for the presence of PGC-1{alpha} mRNA by RT-PCR. As shown in Fig. 1A, a band corresponding to the PGC-1{alpha} fragment was detected in cDNA samples but not in RNA controls. The identity of the band was confirmed by DNA sequencing.


Figure 1
View larger version (29K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 PGC-1{alpha} is present in endothelial cells of human and bovine origin. PGC-1{alpha} expression in HUVECs drives the induction of ETC genes. (A) The presence of PGC-1{alpha} mRNA was determined by RT-PCR analysis of total RNA. PGC-1{alpha} protein was detected by Western blot of WCE. Cells infected with a recombinant PGC-1{alpha} adenovirus (Ad-PGC-1{alpha}) were used as positive control (lower panel). (B) HUVEC were infected with increasing doses of Ad-PGC-1 (0, 5, 12.5, 25, 50, 100 moi), and/or a complementary dose of Ad, and induction of ETC genes was monitored by RT-PCR analysis with specific oligonucleotides, β-actin was used as a negative control. (C) Mitochondrial mass was determined by flow cytometry of cells labeled with Mitotracker Green. Levels are expressed as percentage relative to the values obtained for non-infected cells. (*) P ≥ 0.05.

 
We also tested the presence of PGC-1{alpha} protein in HUVEC and BAEC, WCE by Western blot. As a positive control we used cells infected with a recombinant adenovirus expressing PGC-1{alpha}. We could reproducibly identify PGC-1{alpha} in both HUVEC and BAEC cells (Fig. 1A).

We then decided to investigate whether PGC-1{alpha} activity in the endothelium would result in the induction of oxidative metabolism genes, as has been described in other cell systems [45]. We constructed a recombinant adenovirus expressing HA-tagged PGC-1-{alpha} (Ad-PGC-1) to ensure the ubiquitous expression of PGC-1{alpha} in endothelial cells. HUVEC were infected with increasing doses (moi 1–100) of Ad-PGC-1 or the control empty virus (Ad), and induction of the ETC genes, Cytochrome C (Cyt C), Cytochrome Oxidase subunits II and IV (COXII, COXIV) and ATP Synthetase β subunit (ATPaseß), was tested 72 h post-infection by RT-PCR. We observed a dose-dependent induction of the mRNA expression levels for all the ETC genes tested (Fig. 1B).

To determine if the induction of ETC gene expression did result in an increased mitochondrial mass, we labeled HUVEC infected with Ad, Ad-PGC-1, or non-infected control with Mitotracker Green. Labeled cells were analyzed by flow cytometry. 72 h post-infection, Ad-PGC-1 cells had 50% higher mitochondrial content than control cells (Fig. 1C, upper panel). Fig. 1C lower panel shows the fluorescence signal distribution in a representative experiment. A clear shift to higher fluorescence values can be observed in Ad-PGC-1 cells.

3.2. PGC-1{alpha} induces oxidative stress protective genes
In order to evaluate PGC-1{alpha} activity under mitochondrial oxidative stress, we analyzed whether PGC-1{alpha} was active and able to regulate ETC and lipid metabolism genes in 30 mM glucose [12]. HUVEC infected with Ad, Ad-PGC-1 or non-infected control, were cultured in low (5 mM) and high (30 mM) glucose for 48 h. The results, obtained by rRT-PCR analysis (Fig. 2A) showed that PGC-1{alpha} is able to induce ETC (Cyt C, ATPaseβ, and COXIV) and lipid catabolism genes, Medium-Chain Acyl-CoA Dehydrogenase (MCAD), Carnitine Palmitoyltransferase I (CPT-I), Long-Chain Acyl Co-A Oxidase (ACO) in oxidative stress conditions (Table 1).


Figure 2
View larger version (38K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 2 PGC-1{alpha} induces the expression of ETC genes, lipid catabolism genes, and oxidative stress protective genes in endothelial cells exposed to 5 mM and 30 mM glucose. Cells were cultured in low or high glucose media for 48 h, and total RNA was analyzed by rRT-PCR. Values are relative to those obtained for 18S rRNA. FN-A (fibronectin A) is a negative control. Levels obtained for the control, untreated samples have been assigned the arbitrary value of 1. (A) and (B) HUVEC. (A) Expression of ETC (CytC, COXIV, ATPaseβ), and lipid catabolism genes MCAD, CPT-I, ACO. Inset shows a magnified view of the lower panel. (B) Induction of oxidative stress genes. UCP-2, MnSOD, Catalase, Prx3, Prx5, TRX2, TRXR2 and, Cu/ZnSOD. (C) BAEC. (*) P ≥ 0.05.

 

View this table:
[in this window]
[in a new window]

  		Table 1 Primer pairs used in rRT-PCR to quantify changes in gene expression

 
We then analyzed the effect of PGC-1{alpha} expression on the mRNA levels of the mitochondrial ROS detoxification machinery: MnSOD, Peroxirredoxins 3 and 5 (Prx3, Prx5) mitochondrial Thioredoxin (TRX2), and mitochondrial Thioredoxin Reductase (TRXR2), UCP-2, and catalase. UCP-2 has been shown to be regulated at the transcriptional level by PGC-1{alpha} [45]. Catalase is an enzyme that degrades H2O2 and is mainly localized in peroxisomes. We observed that PGC-1{alpha} was able to induce the expression of all these genes in both normal (5 mM glucose) and oxidative stress (30 mM glucose) conditions. Importantly, the mRNA levels of a cytoplasmic detoxification enzyme, Cu/Zn Superoxide Dismutase (Cu/ZnSOD) were not modulated by PGC-1{alpha}, suggesting that the effect of PGC-1{alpha} is specific for the mitochondrial system (Fig. 2B). We have extended our observations to other endothelial cell systems: BAEC (Fig. 2C) and MAEC (our unpublished results).

3.3. PGC-1 associates with the promoters of MnSOD, UCP-2 and Prx5 genes
In order to evaluate whether PGC-1{alpha} induction of oxidative stress protective genes was the result of the direct interaction of PGC-1{alpha} with their regulatory promoter regions, we carried out ChIP experiments. HUVEC, were cultured in low or high glucose for 48 h. Following chromatin preparation, the DNA fragments were immunoprecipitated and analyzed by rPCR. As shown in Fig. 3, MnSOD, UCP-2 and Prx5 promoter fragments were specifically enriched in the IP ({alpha}-PGC-1) fraction of Ad-PGC-1. Importantly, UCP-2 had already been proposed to be a direct transcriptional target of PGC-1{alpha} [45]. We conclude that the effects of PGC-1{alpha} are likely to be mediated by its direct association with the promoter regions of these genes (Table 2).


Figure 3
View larger version (11K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 3 PGC-1{alpha} associates with the promoter region of MnSOD, UCP-2 and Prx5 genes in HUVEC cells, as determined by ChIP analysis. HUVEC infected with Ad-PGC-1-were cultured in low or high glucose media for 48 h. Following formaldehyde treatment, PGC-1{alpha} was immunoprecipitated from sonicated WCE. In control IP-reactions a non-relevant antibody was used. The co-immunoprecipitated DNA was purified and analyzed by rPCR. β-actin was used as a non-PGC-1{alpha}-target negative control. Values refer to the X-fold enrichment of a particular fragment in the IP sample relative to the input. (*) P ≥ 0.05.

 

View this table:
[in this window]
[in a new window]

  		Table 2 Primer pairs used in ChIP rPCR analysis

 
3.4. PGC-1{alpha} increases cellular levels of mitochondrial antioxidant proteins
We then assessed whether cells overexpressing PGC-1{alpha} modified the cellular content of antioxidant proteins. The results shown in Fig. 4A indicate that PGC-1{alpha} expression increases the levels of MnSOD, Catalase, Prx5, Prx3, UCP-2, TRXR2, and TRX2, in both normal glucose and oxidative stress conditions (30 mM glucose) (Table 1). Similar results were obtained in different endothelial cells systems like BAEC (Fig. 4B) and MAEC (our unpublished results).


Figure 4
View larger version (63K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 4 PGC-1{alpha} increases the expression of antioxidant proteins in low (5 mM) and high (30 mM) glucose conditions. Cells were cultured in low or high glucose media for 48 h, and WCE were analyzed by Western blot with specific antibodies. (A) HUVEC. (B) BAEC.

 
3.5. Expression of PGC-1{alpha} reduces the accumulation of ROS
To establish whether the observed induction of oxidative stress proteins would increase the cellular detoxification capacity, we incubated HUVEC, with 20 µM DMNQ, a quinone that blocks ETC Complex II [10], and induces a dose-dependent production of superoxide [6]. The level of cellular ROS was estimated by CM-H2DCFDA labeling. We observed that PGC-1{alpha} expression reduced the amount of ROS accumulated in DMNQ treated cells by about 50% (Fig. 5A). Since DMNQ is expected to induce the same ROS production in the absence or presence of PGC-1{alpha}, we concluded that PGC-1{alpha} expression does increase the cell detoxification capacity.


Figure 5
View larger version (14K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 5 PGC-1{alpha} expression increases the mitochondrial detoxification capacity. (A) HUVEC were treated with 20 µM DMNQ for 2.5 h and 30 min. (B) HUVEC, (C) BAEC were cultured in low or high glucose media for 48 h. Cells were labeled with CM-H2DCFA and total intracellular ROS content was estimated by flow cytometry. Levels obtained for control, untreated samples, have been assigned the arbitrary value of 1 or 100%. (*) P ≥ 0.05.

 
We then investigated whether PGC-1{alpha} would reduce the levels of ROS present in cells treated with high glucose. HUVEC accumulate about 30% more ROS in 30 mM than in 5 mM glucose. PGC-1{alpha} expression reduced ROS levels by 50% in both low and high glucose conditions (Fig. 5B). Importantly, Ad-PGC-1 cells in 30 mM glucose have about 25% less ROS than control cells in 5 mM glucose, suggesting that PGC-1{alpha} can prevent high glucose dependent oxidative stress. A similar result was obtained in BAEC cells (Fig. 5C).

3.6. PGC-1 can prevent mitochondrial dysfunction
High glucose treatment of HUVEC and other cell types causes a drop in mitochondrial potential that can be attributed to the inhibition of the ETC by ROS [34], and precedes the activation of the apoptotic cascade. The reduced accumulation of ROS, in PGC-1{alpha} expressing cells, might help to prevent mitochondrial dysfunction. Therefore, we determined {Delta}{Psi}m in HUVEC, cultivated in low or high glucose for 48 h. MitoTracker Green labeling was used to estimate mitochondrial mass. Changes in {Delta}{Psi}m were calculated as differences in the TMRM/MitoTracker Green fluorescence ratio. High glucose treatment reduced mitochondrial potential in control HUVEC by 30%. Mitochondrial {Delta}{Psi}m was about 50% higher in cells expressing PGC-1{alpha}. High glucose treatment reduced {Delta}{Psi}m in Ad-PGC-1 cells by only 15%, and therefore was still about 25% higher than in controls in low glucose, supporting the notion that PGC-1{alpha} can prevent mitochondrial dysfunction in stress conditions (Fig. 6A).


Figure 6
View larger version (26K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 6 PGC-1{alpha} expression prevents mitochondrial dysfunction and cell death. (A) HUVECs that express PGC-1{alpha} have a higher {Delta}{Psi}m both in low and high glucose. Relative {Delta}{Psi}m values were calculated as the ratio of the TMREM/Mitotracker Green fluorescence, and referred to the levels obtained for the control, untreated samples, which were assigned the arbitrary value of 100%. (B) PGC-1{alpha} protects HUVEC from apoptotic cell death induced by oxidative stress. HUVEC were exposed to oxidative stress conditions (250 µmol/L H2O2 for 12 h (upper panel) or high glucose media for 24 h (lower panel)), labeled with an annexin V-FITC conjugate and PI, and apoptotic cell death was determined by flow cytometry.

 
3.7. PGC-1{alpha} expression prevents apoptotic cell death
To investigate whether PGC-1{alpha} activity, was relevant to cell survival, we monitored apoptotic cell death of HUVEC under oxidative stress. It has been reported that exposure to ROS, such as H2O2, or stress inducers that are not themselves ROS, like high glucose, induces apoptosis in HUVEC and other endothelial cell types [3,30,48,12]. HUVEC were exposed to 250 µmol/L H2O2, and cell death was monitored by flow cytometry. After 12 h of treatment 90–100% of control cells had undergone apoptosis, but 50% PGC-1{alpha} expressing cells were still alive (PI–, annexin V–) (Fig. 6B). We concluded that the higher detoxification capacity of PGC-1{alpha} expressing cells could prevent apoptotic cell death in oxidative stress conditions.

We next studied whether PGC-1{alpha} could prevent apoptotic death induced by high glucose in HUVEC. We observed that in low glucose about 10% of the control cells died every 24 h. PGC-1{alpha} expressing cells had a slightly lower proportion of apoptotic cells (9%) than controls. In high glucose 20% of the control cells died every 24 h. Only about 12% of PGC-1{alpha}-expressing cells died per day in 30 mM glucose (Fig. 6B), supporting the notion that PGC-1{alpha} expression protects cells from oxidative stress-induced apoptosis.

3.8. PGC-1{alpha} prevents the activation of caspase-9 and caspase-3 in H2O2 treated cells
It has been previously established that induction of apoptosis by H2O2 [30,48] and other oxidative stress agents like high glucose [36,43] proceeds through the activation of the mitochondrial apoptotic cascade, which involves the sequential activation of caspase-9 and caspase-3. The protective effect of PGC-1{alpha} on apoptosis prompted us to investigate whether PGC-1{alpha} activity prevents the activation of the mitochondrial apoptosis cascade. HUVEC were exposed to 250 µM H2O2, and activation of caspase-9 and caspase-3 was monitored at different times in WCE incubated with fluorescent caspase substrates (Fig. 7A). To directly monitor the activation of the caspases within living cells, HUVEC were labeled with fluorescent caspase-9 and caspase-3 substrates, and examined by confocal microscopy (Fig. 7B). Control cells showed the expected sequential activation of caspase-9, that peaked 4.5 h after H2O2 addition, and caspase-3, that peaked 9 h after H2O2 addition. PGC-1{alpha} expression both delayed and reduced the activation of caspase-9 and caspase-3. Caspase-9 activity was lost after 6 h, and caspase-3 activity could not be detected after 12 h. We concluded that PGC-1{alpha} can protect HUVEC from apoptosis induced by H2O2, preventing the activation of the mitochondrial apoptotic cascade.


Figure 7
View larger version (71K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 7 PGC-1{alpha} delays and reduces the sequential activation of caspase 9 and caspase 3 in HUVEC cells treated with H2O2. (A) Caspase 3 and Caspase 9 activity were analyzed in WCE. Values are relative to the signal for the non-treated control cells at time 0, that is given the arbitrary value of 1. (*) P ≥ 0.05. (B) Live cells were labeled with fluorescent substrates for Caspase 3 (green) and Caspase 9 (red) and visualized on a confocal microscope. Control samples were pre-incubated with the caspase inhibitor Z-VAD. (*) P ≥ 0.05.

 
3.9. Suppression of endogenous PGC-1{alpha} expression results in the down-regulation of the mitochondrial detoxification machinery
To determine whether the PGC-1{alpha} protein present in resting primary endothelial cells was required to sustain the basal levels of mitochondrial detoxification enzymes we decided to suppress PGC-1{alpha} expression, transfecting PGC-1{alpha} siRNA or GAPDH siRNA as a negative control in BAEC cells.

As shown in Fig. 8 we were able to suppress PGC-1{alpha} expression at the mRNA (Fig. 8A) and protein (Fig. 8B) levels, and this downregulation resulted in reduced levels of MnSOD, Prx3, Prx5, TRX2 and TRXR2, supporting the notion that endogenous PGC-1{alpha} does indeed regulate their expression.


Figure 8
View larger version (42K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 8 Suppression of PGC-1{alpha} expression in BAEC results in reduced levels of mitochondrial antioxidant proteins. (A) mRNA levels of PGC-1{alpha}, CytC, GAPDH and mitochondrial oxidative stress genes were monitored by rRT-PCR. Values are relative to those obtained for the 18S rRNA. For each gene (except GAPDH itself), values are given as the relative % of levels obtained for the control siRNA GAPDH samples. (*) P ≥ 0.05. (B) Levels of PGC-1{alpha}, CytC, GAPDH and mitochondrial oxidative stress proteins were monitored by Western blot.

 

   4. Discussion
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
 4. Discussion
References
 
Oxidative stress is the leading cause of various pathological conditions that affect systems as diverse as the central nervous system, heart, lung, liver or the vascular wall. However, our understanding of the mechanisms that allow cells to protect themselves from oxidative stress is still very poor. Our results allow us to propose that PGC-1{alpha} is a major transcriptional regulator of the mitochondrial detoxification system.

Our results demonstrate that PGC-1{alpha}, a positive regulator of oxidative metabolism, co-regulates the induction of a set of proteins that participate in the cellular response to mitochondrial oxidative stress. This positive regulation increases the cellular capacity to detoxify mitochondrial ROS, preventing endothelial dysfunction and apoptotic cell death in response to oxidative stress conditions, such as high glucose.

We interpret these results as evidence that reduced ROS levels allow a better function of mitochondrial ETC. Cells that expressed PGC-1{alpha} showed a higher survival rate, supporting the hypothesis that PGC-1{alpha}-mediated increase in the cell scavenging activity enable the mitochondria to respond better to metabolic overload. These results have important implications since they point to PGC-1{alpha} as a potential target for drug development.

Furthermore, we showed that suppression of PGC-1{alpha} expression in BAEC cells by siRNA results in a strong reduction in the levels of the mitochondrial detoxification proteins MnSOD, Prx3, Prx5, TRX2, TRXR2, and UCP-2. These results suggest that the endogenous endothelial PGC-1{alpha} protein plays a crucial protective role in the endothelium.

To our knowledge this is the first report of a mechanism that coordinately regulates the mitochondrial antioxidant defense system at the transcriptional level. In order to support the notion that PGC-1{alpha} could be directly involved in the transcriptional regulation of antioxidant genes, we tested PGC-1{alpha} interaction with the promoter regions of MnSOD [2,17,19,38,40] UCP-2 [15,47], and Prx5. Our data showed that PGC-1{alpha} could be found associated with the regulatory promoter sequences of MnSOD, UCP-2 and Prx5. Importantly, UCP-2 has already been proposed to be a direct target of PGC-1{alpha} transcriptional regulation [45]. We believe that our results indicate that PGC-1{alpha} is likely to be directly involved in the transcriptional regulation of the complete set of oxidative stress genes tested here, although alternative indirect mechanisms are also possible.

One interesting observation that came along with the characterization of PGC-1{alpha} activity in the endothelium was the effect of high glucose on the expression of oxidative stress protective proteins. We observed that high glucose had a positive effect on the mRNA levels of the detoxification genes, both in the absence and presence of PGC-1{alpha}. However, this positive regulation was not paralleled by a corresponding increase in protein levels. We interpret this result as evidence of a dual regulatory mechanism that might render ineffective the initial increase in mRNA levels. Previous studies on the topic do not shed any light on the possible mechanisms involved, although a decrease in the expression levels of protein synthesis genes has been described in streptozotocin-induced diabetic mice [4]. However, future studies will be necessary to elucidate this point.


   Acknowledgements
 
This work was supported by an institutional grant from CNIC, by the Cardiovascular National Network "RECAVA", by European Union grant FEDER 2FD97-1432, Plan Nacional de I+D+I grant SAF2003-01039 and, grant-in-aid from the Spanish Society of Nephrology to S.L. and, by grants Plan Nacional de I+D+I SAF2003-04901 and 04.4/0027.1/2003 from the Consejeria de Educación de la Comunidad de Madrid to M.M. Inmaculada Valle is from October 2003 holder of a CNIC-Bancaja predoctoral fellowship and was previously supported by the "Fundación Renal Iñigo Alvarez de Toledo". María Monsalve is holder of a Ramon y Cajal contract from the Ministerio de Ciencia y Tecnología.

We thank Dr. Luisa Botella and Antonio Quesada for their help with endothelial cell culture, Estrella Soria, Dr. Mariano Redondo, Raquel Nieto, and Pilar Torralbo for their technical assistance. Dr. Ana Aranda, Dr. Juan Bolaños, Dr. Antonio Miranda and Sara Borniquel for careful reading of the manuscript.


   Notes
 
Time for primary review 28 days


   References
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
 4. Discussion
 References
 

  1. Aliev G., Seyidova D., Lamb B.T., Obrenovich M.E., Siedlak S.L., Vinters H.V., et al. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res (2003) 25:665–674.[CrossRef][ISI][Medline]
  2. Bedogni B., Pani G., Colavitti R., Riccio A., Borrello S., Murphy M., et al. Redox regulation of cAMP-responsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependent cell survival. J Biol Chem (2003) 278:16510–16519.[Abstract/Free Full Text]
  3. Cuda G., Paterno R., Ceravolo R., Candigliota M., Perrotti N., Perticone F., et al. Protection of human endothelial cells from oxidative stress: role of Ras-ERK12 signaling. Circulation (2002) 105:968–974.[Abstract/Free Full Text]
  4. Dhahbi J.M., Mote P.L., Cao S.X., Spindler S.R. Hepatic gene expression profiling of streptozotocin-induced diabetes. Diabetes Technol Ther (2003) 5:411–420.[CrossRef][Medline]
  5. Duval C., Negre-Salvayre A., Dogilo A., Salvayre R., Penicaud L., Casteilla L. Increased reactive oxygen species production with antisense oligonucleotides directed against uncoupling protein 2 in murine endothelial cells. Biochem Cell Biol (2002) 80:757–764.[CrossRef][ISI][Medline]
  6. Floreani M., Carpenedo F. The catecholamine-mediated positive inotropic effect of simple quinones is related to superoxide anion generation. J Pharmacol Exp Ther (1992) 260:468–473.[Abstract/Free Full Text]
  7. Galle J., Quaschning T., Seibold S., Wanner C. Endothelial dysfunction and inflammation: what is the link? Kidney Inter Suppl (2003) S45–S49.
  8. Gasdaska P.Y., Berggren M.M., Berry M.J., Powis G. Cloning, sequencing and functional expression of a novel human thioredoxin reductase. FEBS Lett (1999) 442:105–111.[CrossRef][ISI][Medline]
  9. Heinemann U., Buchheim K., Gabriel S., Kann O., Kovacs R., Schuchmann S. Cell death and metabolic activity during epileptiform discharges and status epilepticus in the hippocampus. Prog Brain Res (2002) 135:197–210.[Medline]
  10. Henry T.R., Wallace K.B. Differential mechanisms of cell killing by redox cycling and arylating quinones. Arch Toxicol (1996) 70:482–489.[CrossRef][ISI][Medline]
  11. Huang H., Manton K.G. The role of oxidative damage in mitochondria during aging: a review. Front Biosci (2004) 9:1100–1117.[ISI][Medline]
  12. Ido Y., Carling D., Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes (2002) 51:159–167.[CrossRef][ISI][Medline]
  13. Jenner P. Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci (2001) 24:245–247.[CrossRef][ISI][Medline]
  14. Jerkic M., Rivas-Elena J.V., Prieto M., Carron R., Sanz-Rodriguez F., Perez-Barriocanal F., et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J (2004) 18:609–611.[Abstract/Free Full Text]
  15. Kelly L.J., Vicario P.P., Thompson G.M., Candelore M.R., Doebber T.W., Ventre J., et al. Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology (1998) 139:4920–4927.[Abstract/Free Full Text]
  16. Kelner M.J., Montoya M.A. Structural organization of the human glutathione reductase gene: determination of correct cDNA sequence and identification of a mitochondrial leader sequence. Biochem Biophys Res Commun (2000) 269:366–368.[CrossRef][ISI][Medline]
  17. Kiningham K.K., Xu Y., Daosukho C., Popova B., St Clair D.K. Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2. Biochem J (2001) 353:147–156.[CrossRef][ISI][Medline]
  18. Knoops B., Clippe A., Bogard C., Arsalane K., Wattiez R., Hermans C., et al. Cloning and characterization of AOEB166, a novel mammalian antioxidant enzyme of the peroxiredoxin family. J Biol Chem (1999) 274:30451–30458.[Abstract/Free Full Text]
  19. Kops G.J., Dansen T.B., Polderman P.E., Saarloos I., Wirtz K.W., Coffer P.J., et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature (2002) 419:316–321.[CrossRef][Medline]
  20. Korshunov S.S., Skulachev V.P., Starkov A.A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett (1997) 416:15–18.[CrossRef][ISI][Medline]
  21. Krauss S., Zhang C.Y., Scorrano L., Dalgaard L.T., St-Pierre J., Grey S.T., et al. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest (2003) 112:1831–1842.[CrossRef][ISI][Medline]
  22. Lee S.R., Kim J.R., Kwon K.S., Yoon H.W., Levine R.L., Ginsburg A., et al. Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J Biol Chem (1999) 274:4722–4734.[Abstract/Free Full Text]
  23. Lopez-Ongil S., Hernandez-Perera O., Navarro-Antolin J., Perez de Lema G., Rodriguez-Puyol M., Lamas S., et al. Role of reactive oxygen species in the signalling cascade of cyclosporine A-mediated up-regulation of eNOS in vascular endothelial cells. Br J Pharmacol (1998) 124:447–454.[CrossRef][ISI][Medline]
  24. Lundberg M., Johansson C., Chandra J., Enoksson M., Jacobsson G., Ljung J., et al. Cloning and expression of a novel human glutaredoxin (Grx2) with mitochondrial and nuclear isoforms. J Biol Chem (2001) 276:26269–26275.[Abstract/Free Full Text]
  25. Macmillan-Crow L.A., Cruthirds D.L. Invited review: manganese superoxide dismutase in disease. Free Radic Res (2001) 34:325–336.[ISI][Medline]
  26. Miranda-Vizuete A., Damdimopoulos A.E., Pedrajas J.R., Gustafsson J.A., Spyrou G. Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization. Eur J Biochem (1999) 261:405–412.[ISI][Medline]
  27. Monsalve M., Wu Z., Adelmant G., Puigserver P., Fan M., Spiegelman B.M. Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Mol Cell (2000) 6:307–316.[CrossRef][ISI][Medline]
  28. Munoz C., Castellanos M.C., Alfranca A., Vara A., Esteban M.A., Redondo J.M., et al. Transcriptional up-regulation of intracellular adhesion molecule-1 in human endothelial cells by the antioxidant pyrrolidine dithiocarbamate involves the activation of activating protein-1. J Immunol (1996) 157:3587–3597.[Abstract]
  29. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 404:787–790.[CrossRef][Medline]
  30. Niwa K., Inanami O., Yamamori T., Ohta T., Hamasu T., Karino T., et al. Roles of protein kinase C delta in the accumulation of P53 and the induction of apoptosis in H2O2-treated bovine endothelial cells. Free Radic Res (2002) 36:1147–1153.[CrossRef][ISI][Medline]
  31. Penta J.S., Johnson F.M., Wachsman J.T., Copeland W.C. Mitochondrial DNA in human malignancy. Mutat Res (2001) 488:119–133.[CrossRef][ISI][Medline]
  32. Preston T.J., Abadi A., Wilson L., Singh G. Mitochondrial contributions to cancer cell physiology: potential for drug development. Adv Drug Deliv Rev (2001) 49:45–61.[CrossRef][ISI][Medline]
  33. Puigserver P., Spiegelman B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev (2003) 24:78–90.[Abstract/Free Full Text]
  34. Recchioni R., Marcheselli F., Moroni F., Pieri C. Apoptosis in human aortic endothelial cells induced by hyperglycemic condition involves mitochondrial depolarization and is prevented by N-acetyl-L-cysteine. Metabolism (2002) 51:1384–1388.[CrossRef][ISI][Medline]
  35. Rhee J., Inoue Y., Yoon J.C., Puigserver P., Fan M., Gonzalez F.J., et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A (2003) 100:4012–4017.[Abstract/Free Full Text]
  36. Russell J.W., Golovoy D., Vincent A.M., Mahendru P., Olzmann J.A., Mentzer A., et al. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J (2002) 16:1738–1748.[Abstract/Free Full Text]
  37. Spyrou G., Enmark E., Miranda-Vizuete A., Gustafsson J. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem (1997) 272:2936–2941.[Abstract/Free Full Text]
  38. St Clair D.K., Porntadavity S., Xu Y., Kiningham K. Transcription regulation of human manganese superoxide dismutase gene. Methods Enzymol (2002) 349:306–312.[ISI][Medline]
  39. St-Pierre J., Lin J., Krauss S., Tarr P.T., Yang R., Newgard C.B., et al. Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem (2003) 278:26597–26603.[Abstract/Free Full Text]
  40. Strehlow K., Rotter S., Wassmann S., Adam O., Grohe C., Laufs K., et al. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res (2003) 93:170–177.[Abstract/Free Full Text]
  41. Sun Q.A., Wu Y., Zappacosta F., Jeang K.T., Lee B.J., Hatfield D.L., et al. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases. J Biol Chem (1999) 274:24522–24530.[Abstract/Free Full Text]
  42. Suwa M., Nakano H., Kumagai S. Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J Appl Physiol (2003) 95:960–968.[Abstract/Free Full Text]
  43. Vincent A.M., Brownlee M., Russell J.W. Oxidative stress and programmed cell death in diabetic neuropathy. Ann NY Acad Sci (2002) 959:368–383.[Abstract/Free Full Text]
  44. Watabe S., Hiroi T., Yamamoto Y., Fujioka Y., Hasegawa H., Yago N., et al. SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria. Eur J Biochem (1997) 249:52–60.[ISI][Medline]
  45. Wu Z., Puigserver P., Andersson U., Zhang C., Adelmant G., Mootha V., et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell (1999) 98:115–124.[CrossRef][ISI][Medline]
  46. Yorek M.A. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res (2003) 37:471–480.[CrossRef][ISI][Medline]
  47. Yoshitomi H., Yamazaki K., Tanaka I. Mechanism of ubiquitous expression of mouse uncoupling protein 2 mRNA: control by cis-acting DNA element in 5'-flanking region. Biochem J (1999) 340(Pt 2):397–404.[CrossRef][ISI][Medline]
  48. Yuan J., Cheng J., Qin X. The role of released cytochrome C from mitochondria in the apoptosis of HUVECs induced by hydrogen peroxide. Zhonghua Shao Shang Za Zhi (2001) 17:360–363.[Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Tanaka, L. M. Aleksunes, R. L. Yeager, M. A. Gyamfi, N. Esterly, G. L. Guo, and C. D. Klaassen
NF-E2-Related Factor 2 Inhibits Lipid Accumulation and Oxidative Stress in Mice Fed a High-Fat Diet
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 655 - 664.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
L. Leick, J. F. P. Wojtaszewski, S. T. Johansen, K. Kiilerich, G. Comes, Y. Hellsten, J. Hidalgo, and H. Pilegaard
PGC-1{alpha} is not mandatory for exercise- and training-induced adaptive gene responses in mouse skeletal muscle
Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E463 - E474.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
B. L. Olson, M. B. Hock, S. Ekholm-Reed, J. A. Wohlschlegel, K. K. Dev, A. Kralli, and S. I. Reed
SCFCdc4 acts antagonistically to the PGC-1{alpha} transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis
Genes & Dev., January 15, 2008; 22(2): 252 - 264.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
H. LIANG, Y. BAI, Y. LI, A. RICHARDSON, and W. F. WARD
PGC-1{alpha}-Induced Mitochondrial Alterations in 3T3 Fibroblast Cells
Ann. N.Y. Acad. Sci., April 1, 2007; 1100(1): 264 - 279.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. Andrulionyte, T. Kuulasmaa, J.-L. Chiasson, M. Laakso, and for the STOP-NIDDM Study Group
Single Nucleotide Polymorphisms of the Peroxisome Proliferator-Activated Receptor-{alpha} Gene (PPARA) Influence the Conversion From Impaired Glucose Tolerance to Type 2 Diabetes: The STOP-NIDDM Trial
Diabetes, April 1, 2007; 56(4): 1181 - 1186.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S. Borniquel, I. Valle, S. Cadenas, S. Lamas, and M. Monsalve
Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1{alpha}
FASEB J, September 1, 2006; 20(11): 1889 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
B. Iglseder, H. Oberkofler, T. K. Felder, K. Klein, B. Paulweber, F. Krempler, D. A. Tregouet, and W. Patsch
Associations of PPARGC1A Haplotypes With Plaque Score but Not With Intima-Media Thickness of Carotid Arteries in Middle-Aged Subjects
Stroke, September 1, 2006; 37(9): 2260 - 2265.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
R. Rodriguez-Calvo, M. Jove, T. Coll, A. Camins, R. M. Sanchez, M. Alegret, M. Merlos, M. Pallas, J. C. Laguna, and M. Vazquez-Carrera
PGC-1{beta} Down-Regulation Is Associated With Reduced ERR{alpha} Activity and MCAD Expression in Skeletal Muscle of Senescence-Accelerated Mice.
J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2006; 61(8): 773 - 780.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. Andrulionyte, P. Peltola, J.-L. Chiasson, M. Laakso, and for the STOP-NIDDM Study Group
Single Nucleotide Polymorphisms of PPARD in Combination With the Gly482Ser Substitution of PGC-1A and the Pro12Ala Substitution of PPARG2 Predict the Conversion From Impaired Glucose Tolerance to Type 2 Diabetes: The STOP-NIDDM Trial.
Diabetes, July 1, 2006; 55(7): 2148 - 2152.
[Abstract] [Full Text] [PDF]

Home page